Innate Pharma SA vs Relay Therapeutics
Relay Therapeutics is the larger business, with $15.4m of revenue in fiscal 2025 against $10.2m for Innate Pharma SA (1.5 times as much). Relay Therapeutics grew faster (53.4% against -53.2%). Innate Pharma SA kept more of each dollar of sales as profit: a net margin of -546.1% against -1800.6%.
| Latest fiscal year | Innate Pharma SAIPHA, 2025 | Relay TherapeuticsRLAY, 2025 |
|---|---|---|
| Revenue | $10.2m | $15.4m |
| Revenue growth | -53.2% | 53.4% |
| Net income | −$55.6m | −$276m |
| Operating margin | -599.8% | -1971.6% |
| Net margin | -546.1% | -1800.6% |
| Return on equity | — | -41.1% |
| Free cash flow | −$59.8m | −$236m |
| Cash | $33.0m | $84.0m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 192 |
| Market value | $120m | $3.84bn |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 40 sales |